Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Burning Rock Biotech Limited Sponsored ADR stock logo
BNR
Burning Rock Biotech
$17.85
+6.5%
$18.76
$2.49
$41.72
$187.73M1.4926,767 shs960 shs
Castle Biosciences, Inc. stock logo
CSTL
Castle Biosciences
$18.56
+2.2%
$24.52
$14.59
$44.28
$564.78M1.11401,284 shs218,935 shs
Charming Medical Ltd stock logo
MCTA
Charming Medical
$29.36
$29.36
$4.30
$31.70
$497.36MN/AN/A4.25 million shs
Personalis, Inc. stock logo
PSNL
Personalis
$6.77
+5.9%
$6.70
$3.84
$11.50
$714.51M1.961.64 million shs1.36 million shs
A Guide To High-Short-Interest Stocks Cover

MarketBeat's analysts have just released their top five short plays for May 2026. Learn which stocks have the most short interest and how to trade them. Click the link to see which companies made the list.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Burning Rock Biotech Limited Sponsored ADR stock logo
BNR
Burning Rock Biotech
+3.92%+2.82%-2.46%-42.22%+613.84%
Castle Biosciences, Inc. stock logo
CSTL
Castle Biosciences
-2.58%-26.67%-22.86%-43.10%+6.58%
Charming Medical Ltd stock logo
MCTA
Charming Medical
0.00%0.00%0.00%0.00%+2,935,999,900.00%
Personalis, Inc. stock logo
PSNL
Personalis
+5.79%+5.27%+1.27%-23.84%+24.32%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Burning Rock Biotech Limited Sponsored ADR stock logo
BNR
Burning Rock Biotech
$17.85
+6.5%
$18.76
$2.49
$41.72
$187.73M1.4926,767 shs960 shs
Castle Biosciences, Inc. stock logo
CSTL
Castle Biosciences
$18.56
+2.2%
$24.52
$14.59
$44.28
$564.78M1.11401,284 shs218,935 shs
Charming Medical Ltd stock logo
MCTA
Charming Medical
$29.36
$29.36
$4.30
$31.70
$497.36MN/AN/A4.25 million shs
Personalis, Inc. stock logo
PSNL
Personalis
$6.77
+5.9%
$6.70
$3.84
$11.50
$714.51M1.961.64 million shs1.36 million shs
A Guide To High-Short-Interest Stocks Cover

MarketBeat's analysts have just released their top five short plays for May 2026. Learn which stocks have the most short interest and how to trade them. Click the link to see which companies made the list.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Burning Rock Biotech Limited Sponsored ADR stock logo
BNR
Burning Rock Biotech
+3.92%+2.82%-2.46%-42.22%+613.84%
Castle Biosciences, Inc. stock logo
CSTL
Castle Biosciences
-2.58%-26.67%-22.86%-43.10%+6.58%
Charming Medical Ltd stock logo
MCTA
Charming Medical
0.00%0.00%0.00%0.00%+2,935,999,900.00%
Personalis, Inc. stock logo
PSNL
Personalis
+5.79%+5.27%+1.27%-23.84%+24.32%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Burning Rock Biotech Limited Sponsored ADR stock logo
BNR
Burning Rock Biotech
1.00
SellN/AN/A
Castle Biosciences, Inc. stock logo
CSTL
Castle Biosciences
2.90
Moderate Buy$44.57140.20% Upside
Charming Medical Ltd stock logo
MCTA
Charming Medical
1.00
SellN/AN/A
Personalis, Inc. stock logo
PSNL
Personalis
2.57
Moderate Buy$11.0062.48% Upside

Current Analyst Ratings Breakdown

Latest BNR, PSNL, CSTL, and MCTA Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/13/2026
Castle Biosciences, Inc. stock logo
CSTL
Castle Biosciences
Lower Price TargetBuy$50.00 ➝ $40.00
5/12/2026
Personalis, Inc. stock logo
PSNL
Personalis
Lower Price TargetEqual Weight$10.00 ➝ $9.00
5/11/2026
Personalis, Inc. stock logo
PSNL
Personalis
Lower Price TargetBuy$13.00 ➝ $11.00
5/7/2026
Castle Biosciences, Inc. stock logo
CSTL
Castle Biosciences
DowngradeSell (D)Sell (D-)
5/7/2026
Castle Biosciences, Inc. stock logo
CSTL
Castle Biosciences
Lower Price TargetOutperform$44.00 ➝ $43.00
4/27/2026
Castle Biosciences, Inc. stock logo
CSTL
Castle Biosciences
UpgradeHoldStrong-Buy
4/21/2026
Personalis, Inc. stock logo
PSNL
Personalis
Reiterated RatingSell (D-)
4/20/2026
Burning Rock Biotech Limited Sponsored ADR stock logo
BNR
Burning Rock Biotech
Reiterated RatingSell (D-)
4/20/2026
Castle Biosciences, Inc. stock logo
CSTL
Castle Biosciences
Lower Price TargetBuy$50.00 ➝ $40.00
3/5/2026
Personalis, Inc. stock logo
PSNL
Personalis
Lower Price TargetEqual Weight$11.00 ➝ $10.00
3/2/2026
Castle Biosciences, Inc. stock logo
CSTL
Castle Biosciences
UpgradeBuy
(Data available from 5/14/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Burning Rock Biotech Limited Sponsored ADR stock logo
BNR
Burning Rock Biotech
$77.16M2.43N/AN/A$7.28 per share2.45
Castle Biosciences, Inc. stock logo
CSTL
Castle Biosciences
$344.23M1.63$1.11 per share16.74$15.21 per share1.22
Charming Medical Ltd stock logo
MCTA
Charming Medical
N/AN/AN/AN/AN/AN/A
Personalis, Inc. stock logo
PSNL
Personalis
$64.52M10.99N/AN/A$2.43 per share2.79
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Burning Rock Biotech Limited Sponsored ADR stock logo
BNR
Burning Rock Biotech
-$7.92M-$0.79N/AN/AN/A-10.27%-9.98%-6.69%6/2/2026 (Estimated)
Castle Biosciences, Inc. stock logo
CSTL
Castle Biosciences
-$24.16M-$0.44N/AN/AN/A-3.78%-2.77%-2.30%N/A
Charming Medical Ltd stock logo
MCTA
Charming Medical
N/AN/AN/AN/AN/AN/AN/AN/AN/A
Personalis, Inc. stock logo
PSNL
Personalis
-$81.27M-$1.02N/AN/AN/A-148.11%-43.52%-32.92%N/A

Latest BNR, PSNL, CSTL, and MCTA Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
6/2/2026Q1 2026
Burning Rock Biotech Limited Sponsored ADR stock logo
BNR
Burning Rock Biotech
-$2.2884N/AN/AN/A$19.21 millionN/A
5/7/2026Q1 2026
Personalis, Inc. stock logo
PSNL
Personalis
-$0.23-$0.29-$0.06-$0.29$14.49 million$15.47 million
5/6/2026Q1 2026
Castle Biosciences, Inc. stock logo
CSTL
Castle Biosciences
-$0.49-$0.49N/A-$0.49$79.23 million$84.23 million
3/13/2026Q4 2025
Burning Rock Biotech Limited Sponsored ADR stock logo
BNR
Burning Rock Biotech
N/A-$0.21N/A-$0.21N/A$18.05 million
2/26/2026Q4 2025
Castle Biosciences, Inc. stock logo
CSTL
Castle Biosciences
-$0.23-$0.08+$0.15-$0.08$81.19 million$81.88 million
2/26/2026Q4 2025
Personalis, Inc. stock logo
PSNL
Personalis
-$0.31-$0.26+$0.05-$0.26$17.12 million$17.35 million
2/14/2026Q4 2025
Burning Rock Biotech Limited Sponsored ADR stock logo
BNR
Burning Rock Biotech
N/A-$0.21N/A-$0.21N/A$18.05 million
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Burning Rock Biotech Limited Sponsored ADR stock logo
BNR
Burning Rock Biotech
N/AN/AN/AN/AN/A
Castle Biosciences, Inc. stock logo
CSTL
Castle Biosciences
N/AN/AN/AN/AN/A
Charming Medical Ltd stock logo
MCTA
Charming Medical
N/AN/AN/AN/AN/A
Personalis, Inc. stock logo
PSNL
Personalis
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Burning Rock Biotech Limited Sponsored ADR stock logo
BNR
Burning Rock Biotech
N/A
2.99
2.79
Castle Biosciences, Inc. stock logo
CSTL
Castle Biosciences
0.02
6.75
6.53
Charming Medical Ltd stock logo
MCTA
Charming Medical
N/AN/AN/A
Personalis, Inc. stock logo
PSNL
Personalis
N/A
6.61
6.44

Institutional Ownership

CompanyInstitutional Ownership
Burning Rock Biotech Limited Sponsored ADR stock logo
BNR
Burning Rock Biotech
30.03%
Castle Biosciences, Inc. stock logo
CSTL
Castle Biosciences
92.60%
Charming Medical Ltd stock logo
MCTA
Charming Medical
N/A
Personalis, Inc. stock logo
PSNL
Personalis
61.91%

Insider Ownership

CompanyInsider Ownership
Burning Rock Biotech Limited Sponsored ADR stock logo
BNR
Burning Rock Biotech
30.30%
Castle Biosciences, Inc. stock logo
CSTL
Castle Biosciences
6.10%
Charming Medical Ltd stock logo
MCTA
Charming Medical
N/A
Personalis, Inc. stock logo
PSNL
Personalis
4.20%
CompanyEmployeesShares OutstandingFree FloatOptionable
Burning Rock Biotech Limited Sponsored ADR stock logo
BNR
Burning Rock Biotech
1,39010.52 million7.33 millionNot Optionable
Castle Biosciences, Inc. stock logo
CSTL
Castle Biosciences
54030.33 million28.48 millionOptionable
Charming Medical Ltd stock logo
MCTA
Charming Medical
4916.94 millionN/AN/A
Personalis, Inc. stock logo
PSNL
Personalis
400104.72 million100.32 millionOptionable

Recent News About These Companies

Guggenheim Remains a Buy on Personalis (PSNL)
Personalis: Q1 Earnings Snapshot
Personalis (PSNL) Q1 2026 Earnings Transcript
Personalis Q1 Earnings Call Highlights

New MarketBeat Followers Over Time

Media Sentiment Over Time

Burning Rock Biotech stock logo

Burning Rock Biotech NASDAQ:BNR

$17.84 +1.09 (+6.47%)
As of 01:06 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Burning Rock Biotech Limited primarily develops and commercializes cancer therapy selection tests in the People's Republic of China. It operates in three segments: Central Laboratory Business, In-Hospital Business, and Pharma Research and Development Services. The company primarily offers next-generation sequencing-based tissue and liquid biopsy cancer therapy selection and prognosis prediction tests for various range of cancer types, including lung cancer, gastrointestinal cancer, prostate cancer, breast cancer, lymphomas, thyroid cancer, colorectal cancer, ovarian cancer, pancreatic cancer, and bladder cancer using tissue and liquid biopsy samples. Its principal products include OncoCompass IO, a corresponding test for liquid biopsy samples; OncoScreen IO, a pan-cancer test for tissue samples; and OncoCompass Target, a ctDNA liquid biopsy-based test for NSCLC. In addition, the company provides ColonCore for assessing microsatellite loci related to MSI status and detecting mutations in genes associated with gastrointestinal cancers; and brPROPHET, a pre-operative ctDNA detection and post-operative MRD calling for relapsed patients. Further, it has development and commercialization agreement with Myriad Genetics, Inc. to in-license Myriad myChoice tumor testing in China; licensing agreement with Oncocyte Corporation to in-license DetermaRx, a risk stratification test for early stage lung cancer patients in China; and collaborations on clinical trials and research studies with AstraZeneca, Bayer, Johnson & Johnson, CStone, BeiGene, Abbisko Therapeutics, and IMPACT Therapeutics and Merck KGaA. Additionally, the company offers OncoMaster, an automatic NGS data analysis and report interpretation machine for in-hospital model. Burning Rock Biotech Limited was incorporated in 2014 and is headquartered in Guangzhou, China.

Castle Biosciences stock logo

Castle Biosciences NASDAQ:CSTL

$18.56 +0.41 (+2.24%)
As of 01:09 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Castle Biosciences, Inc., a molecular diagnostics company, provides testing solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus, uveal melanoma, and mental health conditions. It offers DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test to identify the risk of metastasis for patients diagnosed with invasive cutaneous melanoma; DecisionDx-SCC, a proprietary risk stratification GEP test for patients with cutaneous squamous cell carcinoma; MyPath Melanoma, a test used for patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a spatial omics test to predict future development of high-grade dysplasia and/or esophageal cancer in patients with non-dysplastic, indefinite dysplasia, or low-grade dysplasia Barrett's esophagus. In addition, the company provides DecisionDx-UM test, a proprietary risk stratification GEP test that predicts the risk of metastasis for patients with uveal melanoma; and IDgenetix, a pharmacogenomic test that helps guide drug treatment for major depressive disorder, schizophrenia, bipolar disorder, anxiety disorders, social phobia, obsessive-compulsive personality disorder, post-traumatic stress disorder, and attention deficit hyperactivity disorder. It offers its products to skin cancer, gastroenterology, and mental health markets. The company was incorporated in 2007 and is headquartered in Friendswood, Texas.

Charming Medical stock logo

Charming Medical NASDAQ:MCTA

$29.36 0.00 (0.00%)
As of 05/13/2026 03:30 PM Eastern

We are a Hong Kong-based provider of Traditional Chinese Medicine (TCM)-inspired therapies and products. We offer a wide range of beauty, wellness, and postpartum services and products rooted and influenced by the principles and practices of TCM, such as the use of herbal ingredients, acupuncture techniques, Tuina massage, and dietary guidance. Operating under the Beauty Lab Group (“Beauty Lab”) brand, our Operating Subsidiaries in Hong Kong offer a wide range of TCM-inspired beauty, wellness, and postpartum therapies and products through our four wellness centers in Hong Kong. Our services are designed to meet diverse health improvement needs, including alleviating premenstrual syndrome, menstrual irregularities, dysmenorrhea, leukorrhea, pelvic inflammatory disease, menopausal care, breast health, and other common women’s health conditions. We believe that our TCM-inspired herbal therapies can help balance the female endocrine system and improve women’s constitution and overall health. Additionally, the Operating Subsidiaries offer TCM-inspired therapies tailored to men. We offer a wide range of beauty, wellness, and postpartum services for women with a focus on utilizing TCM approaches in addressing women’s health issues. Our beauty, wellness, and postpartum services include but are not limited to womb-warming therapy, BTS (Beauty, Tailor-made, Slim) pelvic detox therapy, agarwood moxibustion therapy, TCM-inspired prenatal massage, and Indonesian traditional abdominal binding. In addition, under the “Beauty Lab” brand, we also offer supplements products, including (i) TCM-inspired supplements products, such as Beauty Lab home herbal uterine care patch, probiotic intimate wash, and Yin nourishing pill sets, designed to support uterine health, improve physical weakness, and balance endocrine functions for female customers; and (ii) beauty products, including ginseng soothing anti-allergy moisturizing wash, which provide comprehensive care for skin issues, and scalp health. Moreover, we also offer consultancy services to provide TCM-inspired therapy technical training and dietary therapy training to other well-established and reputable beauty salons, massage centers, and similar institutions. In March 2025, we launched a franchise model for our Beauty Lab brand, granting exclusive rights to independent third parties (the “Franchisees”) to operate branded beauty and wellness outlets. Franchisees are authorized to offer services such as scalp and hair care and women’s wellness services under the Beauty Lab brand. We derive franchise-related revenue mainly from initial franchise fees, royalty and promotional fees, brand management fees, training and administration fees. As of March 31, 2025 and as of the date of this prospectus, we had 1 and 3 franchisees, respectively. We generated revenue of $6,221,751 and $6,015,375, respectively, and achieved a net income of $1,199,085 and $821,743, respectively, for the years ended March 31, 2025 and 2024. We generated revenue primarily through the following: (i) beauty, wellness, and postpartum services; (ii) sales of products; (iii) consultancy services; and (iv) franchise activities. For the fiscal years ended March 31, 2025 and 2024, the revenue from beauty, wellness, and postpartum services amounted to $5,967,277 and $5,813,814, representing 96.0% and 96.6% of total revenue, respectively. The revenue from sales of products was $207,766 and $88,992 for the fiscal years ended March 31, 2025 and 2024, representing 3.2% and 1.5% of total revenue, respectively. The revenue from consultancy services was nil and $112,569 for the fiscal years ended March 31, 2025 and 2024, representing 0% and 1.9% of total revenue, respectively. The revenue from franchise activities was $46,708 and nil for the fiscal years ended March 31, 2025 and 2024, representing 0.8% and 0% of total revenue, respectively. Our principal executive office is located Hong Kong.

Personalis stock logo

Personalis NASDAQ:PSNL

$6.77 +0.38 (+5.95%)
As of 01:09 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Personalis, Inc. develops and markets advanced cancer genomic tests and analytics primarily in the United States, Europe, and the Asia-Pacific. Its tests and analytics are used by pharmaceutical companies for translational research, biomarker discovery, and development of personalized cancer therapies, as well as advanced tests are used by physicians to detect cancer recurrence, monitor cancer evolution, and uncover insights for therapy selection. The company offers NeXT Personal, a tumor-informed liquid biopsy test for detection of minimal residual disease (MRD) and recurrence in cancer; and ImmunoID NeXT, a tissue-based test that combines whole exome (DNA) and whole transcriptome (RNA) sequencing data with advanced analytics to provide a multi-dimensional view of the tumor and the tumor microenvironment from a single sample. It also provides NeXT Personal Dx, a tumor-informed liquid biopsy test for detection of MRD and recurrence in cancer; and NeXT Dx, a comprehensive tumor profiling test that unlocks the entire exome (DNA) and transcriptome (RNA) with matched tumor-normal analysis. In addition, the company performs whole exome sequencing (WES) of cancer tissue and matched blood samples for diagnostic companies as an input to their products; and whole genome sequencing (WGS) on human samples for research projects, such as population sequencing initiatives, as well as offers sequencing and data analysis services to support population sequencing initiatives. Its customers include pharmaceutical companies, biopharmaceutical companies, diagnostics companies, universities, non-profits, government entities, and patients. The company was incorporated in 2011 and is headquartered in Fremont, California.